Topoisomerase II (topo II) is a ubiquitous enzyme that is essential for cell survival through its role in regulating DNA topology and chromatid separation. Topo II can be poisoned by common chemotherapeutics (such as doxorubicin and etoposide), leading to the accumulation of cytotoxic enzyme-linked DNA doublestranded breaks. In contrast, nonbreak-inducing topo II catalytic inhibitors have also been described and have more limited use in clinical chemotherapy. These agents, however, may alter the efficacy of regimens incorporating topo II poisons. We previously identified salicylate, the primary metabolite of aspirin, as a novel catalytic inhibitor of topo II. We have now determined the mechanism by which salicylate inhibits topo II. As catalytic inhibitors can act at a number of steps in the topo II catalytic cycle, we used multiple independent, biochemical approaches to interrogate the catalytic cycle. Furthermore, as mammalian cells express two isoforms of topo II (a and b), we examined whether salicylate was isoform selective. Our results demonstrate that salicylate is unable to intercalate DNA, and does not prevent enzyme-DNA interaction, nor does it promote stabilization of topo IIa in closed clamps on DNA. Although salicylate decreased topo IIa ATPase activity in a dose-dependent noncompetitive manner, this was secondary to salicylate-mediated inhibition of DNA cleavage. Surprisingly, comparison of salicylate's effects using purified human topo IIa and topo IIb revealed that salicylate selectively inhibits the a isoform. These findings provide a definitive mechanism for salicylate-mediated inhibition of topo IIa and provide support for further studies determining the basis for its isoform selectivity.
Introduction
For cells to package their genetic material within the restricted boundaries of a nucleus, DNA must be supercoiled and organized into discrete higher-order chromatin structures. Yet, relaxation of chromatin must be similarly regulated to permit orderly DNA replication and gene expression. To accomplish these tasks, cells express at least one type IIA DNA topoisomerase, an essential enzyme required for the maintenance and regulation of DNA topology (Nitiss, 2009a; Vos et al., 2011) .
The roles of eukaryotic topoisomerase (topo) II in DNA replication and gene expression have been well established (Nitiss, 2009a; Vos et al., 2011) . As the DNA helix is unwound, positive and negative supercoils are generated in front of and trailing the replication machinery, respectively. These topological structures can act as physical barriers to replication and transcription and must be resolved (Fachinetti et al., 2010; Baxter et al., 2011) . In addition, newly synthesized sister chromatids are intertwined after replication, requiring decatenation by topo II prior to chromosome segregation during anaphase (Germe et al., 2009; Luo et al., 2009 ). Mammalian cells express two isoforms of topo II (topo IIa and topo IIb). Whereas the a isoform is predominant in actively replicating cells and its expression level rises and falls through the cell cycle, the b isoform is expressed at constant levels throughout the cell cycle and has been found to be necessary for regulated transcription and neural development (Ju et al., 2006; Vávrová and Sim unek, 2012) . Chemotherapeutics targeting topo II have been of great utility in clinical oncology. Widely used chemotherapeutics, such as doxorubicin and etoposide, chosen initially for their potency at inducing cell death, were subsequently discovered to target topo II. These agents, termed topo II poisons, are characterized by their ability to stabilize the topo II-DNA cleavable complex, leading to the accumulation of DNA doublestranded breaks in the cell. However, treatment with topo II poisons is associated with an increased risk of secondary malignancies and cardiotoxicity (Lipshultz et al., 2010; Vrooman et al., 2011) . Recent work has uncovered that these events are mediated through topo IIb (Cowell et al., 2012; Zhang et al., 2012) .
In addition to the well-known topo II poisons, a diverse range of compounds has been identified that inhibit topo II activity without stabilizing DNA strand breaks; these are collectively termed catalytic inhibitors and inhibit topo II at any one of several stages of its catalytic cycle (Larsen et al., 2003; Pommier, 2013) . For example, intercalators, by distorting the DNA helical structure, interfere with topo II-DNA binding (Sørensen et al., 1992; Braña et al., 2001) ; ATPase inhibitors prevent ATP hydrolysis and/or the release of ADP and free phosphate that is required for strand passage (Vaughn et al., 2005; Hu et al., 2006) ; and bisdioxopiperazines, including ICRF-187 (4-[(2S)-2-(3,5-dioxopiperazin-1-yl)propyl]piperazine-2,6-dione hydrochloride) and butan-2-yl]piperazine-2,6-dione), inhibit the enzyme in a closed clamp conformation, such that the enzyme cannot be released from DNA after religation (Morris et al., 2000; Classen et al., 2003; Germe and Hyrien, 2005) . These compounds have been examined for therapeutic potential and have been shown to reduce both topo II poisonassociated cardiotoxicity and the incidence of secondary malignancies (Lipshultz et al., 2010; Vrooman et al., 2011) . However, their use as primary agents in the treatment of cancer has not been realized.
We recently identified salicylate, the primary active metabolite of aspirin (acetylsalicylic acid) and one of the most widely used drugs worldwide, as a novel catalytic inhibitor of topo II (Bau and Kurz, 2011) . Using cultured human breast cancer cells, we demonstrated that a brief pretreatment with salicylate decreases doxorubicin-or etoposide-induced DNA damage by preventing topo II-mediated DNA double-stranded break formation, thereby decreasing the cytotoxicity of topo II poisons (Bau and Kurz, 2011) . Our previous work demonstrated that these salicylate-mediated effects are specific for topo II and are independent of other known functions of salicylate (Bau and Kurz, 2011) . We now extend our work to demonstrate the mechanism of topo II catalytic inhibition by salicylate and describe the selectivity of salicylate for the a isoform of topo II.
Materials and Methods
Reagents. Sodium salicylate, novobiocin, ICRF-193, and amsacrine (mAMSA) were purchased from Sigma-Aldrich (Oakville, ON, Canada). Hypericin was purchased from EMD Millipore (Billerica, MA). Stock solutions of hypericin, mAMSA, and ICRF-193 were prepared in dimethylsulfoxide, protected from light, and stored in aliquots at 220°C. Novobiocin was prepared in distilled H 2 O and stored at 220°C. Salicylate was prepared freshly in distilled H 2 O prior to each use. All other chemicals and reagents were of the highest quality available, nuclease free, and purchased from Sigma-Aldrich or EMD Chemicals (Gibbstown, NJ). Recombinant human topo IIa was purchased from Topogen (Port Orange, FL), and recombinant apyrase was purchased from New England Biolabs (Ipswich, MA). Recombinant human topo IIb was prepared, as previously described (Austin et al., 1995) .
Cell Culture and Preparation of Cell Extracts. For experiments requiring nuclear extracts, logarithmically growing MCF-7 human breast cancer cells were cultured in Dulbecco's modified Eagle's medium (Sigma-Aldrich) supplemented with 10% fetal bovine serum (Sigma-Aldrich). Cells were maintained at 37°C in a humidified atmosphere containing 5% CO 2 . Cells were grown to 70-80% confluence and harvested, washed twice in ice-cold phosphate-buffered saline (137 mM NaCl, 2.7 mM KCl, 10 mM Na 2 HPO 4 , 1.8 mM KH 2 PO 4 ), and resuspended in hypotonic lysis buffer (30 mM Tris, pH 7.5, 3 mM MgCl 2 , 10 mM KCl, 20% v/v glycerol, 1% v/v Triton X-100) containing protease inhibitors (1 mM phenylmethylsulfonylfluoride, 2 mg ml 21 aprotinin, 2 mg ml 2 1 leupeptin, 1 mg ml 2 1 pepstatin A). The cell suspension was then incubated on ice for 10 minutes prior to centrifugation at 12,000g for 2 minutes at 4°C. The supernatant was discarded and the nuclear pellet was resuspended in 300 mM NaCl extraction buffer (30 mM Tris, pH 7.5, 3 mM MgCl 2 , 300 mM NaCl) containing protease inhibitors. Following an additional 30-minute incubation on ice, the suspension was centrifuged at 12,000g for 2 minutes at 4°C. Protein quantitation in the supernatant fraction was determined using a detergent-compatible protein assay (Bio-Rad, Hercules, CA) prior to snap-freezing aliquots in liquid nitrogen and storage at 280°C.
Ethidium Bromide Displacement Assay. The displacement of ethidium bromide from DNA was measured, as previously described (Fortune and Osheroff, 1998; Graves, 2001) . In brief, increasing concentrations of salicylate were added to samples containing 5 nM pBluescript-KS 1 plasmid and 1 mM ethidium bromide in a fluorescence buffer (10 mM HEPES, pH 7.9, 100 mM KCl, 5 mM MgCl 2 , 0.1 mM EDTA, pH 8.0). Fluorescence emission spectra (l max 595 nm; excitation 510 nm) were obtained in replicates of eight for each drug concentration and compared with those obtained using mAMSA, a topo II poison that is known to intercalate DNA and displace ethidium bromide at high drug concentrations.
Topoisomerase I-Mediated DNA-Unwinding Assay. As an alternative measure to examine DNA intercalation, a topo I-based assay was carried out according to manufacturer's protocol. In brief, recombinant human topo I (4 U; Topogen) was incubated with 150 ng supercoiled pHOT1 plasmid (Topogen) in a reaction buffer (10 mM Tris-HCl, pH 7.9, 1 mM EDTA, pH 8.0, 150 mM NaCl, 1 mg ml 21 bovine serum albumin, 0.1 mM spermidine, and 5% v/v glycerol) at 37°C for 30 minutes. Subsequently, salicylate or mAMSA was added to the reaction and incubated an additional 30 minutes at 37°C. Reactions were stopped by the addition of SDS to a final concentration of 1% w/v, and topo I was digested by the addition of proteinase K (50 mg) and incubation for 1 hour at 56°C. Samples were resolved on a 1% w/v agarose gel containing 0.2 mg ml 21 chloroquine in 1Â Tris-phosphate-EDTA buffer (36 mM Tris, pH 7.7, 1 mM EDTA, 30 mM NaH 2 PO 4 ) overnight at 10 V. DNA bands were visualized after staining with 1 mg ml 21 ethidium bromide. Electrophoretic Mobility Shift Assay. The binding of topo II to DNA was evaluated using electrophoretic mobility shift assays (EMSA), as previously described (Kurz et al., 2000; Peebles et al., 2001) , with the following modifications. Oligonucleotides containing a strong topo II binding site corresponding to residues 87-126 of the pBR322 plasmid were annealed and end labeled with [a-32 P]deoxycytidine triphosphate (PerkinElmer, Waltham, MA). Nuclear extracts (4 mg) from MCF-7 cells were incubated with ∼5-10 fmol of the radiolabeled binding site in reaction buffer (20 mM Tris, pH 7.6, 50 mM KCl, 1 mM EDTA, 2 mM MgCl 2 , 10% v/v glycerol, 0.5 mg poly[dI:dC]) on ice for 30 minutes. Reaction products were resolved on a 4% acrylamide/0.5Â Tris/borate/EDTA gel, dried using a gel dryer, and exposed to film. For competition assays, reactions were incubated with increasing molar concentrations of unlabeled topo II binding site or an unlabeled nonspecific double-stranded oligonucleotide. For supershift assays, a polyclonal rabbit antiserum raised to a fragment of human topo IIa (amino acids 857-1448) (a kind gift of Dr. David Kroll, Nature Research Center, Raleigh, NC) was incubated with the extract alone for 30 minutes on ice prior to the addition of the radiolabeled oligo and continued incubation for 30 minutes on ice. Control experiments contained preimmune serum from the same animal. For experiments measuring the effect of salicylate on topo II-DNA binding, nuclear extract, salicylate, and buffer were first incubated for 10 minutes on ice prior to the addition of radiolabeled binding site and continued incubation for 30 minutes. In experiments in which purified topo IIa (Topogen) was used, reaction conditions were adjusted to include 1.6 fmol each of radiolabeled binding site and protein (1:1 ratio). The reaction buffer did not contain poly[dI:dC], but was otherwise identical Salicylate Inhibits Topoisomerase IΙa DNA Cleavage to that used for nuclear extracts, as were the binding conditions. Reaction products were resolved on a 6% acrylamide/0.5Â Tris/borate/ EDTA gel and processed, as described above.
Closed-Clamp Assay. Topo IIa closed clamp formation was assayed as previously described (Roca and Wang, 1992; Roca, 2001) with modifications (Vaughn et al., 2005) . Reactions contained topo IIa (33 nM) and 0.6 mg (3 pmol) pBluescript-KS 1 plasmid DNA in reaction buffer A (10 mM Tris, pH 7.7, 50 mM NaCl, 50 mM KCl, 0.1 mM EDTA, 10 mM MgCl 2 , 0.1 mg ml 21 bovine serum albumin) with either 0.5 mM ATP, 0.5 mM adenylyl-imidodiphosphate (AMP-PNP), or 0.5 mM ATP with 10 mM salicylate. Samples were incubated at 37°C for 5 minutes prior to stopping the reaction by the addition of NaCl/ EDTA to final concentrations of 200 mM and 10 mM, respectively. Samples were then incubated at room temperature on glass fiber filters (GF/C; Whatman, Piscataway, NJ) for 10 minutes prior to centrifugation at 50g for 2 minutes. Filters were subsequently washed twice with buffer A, pooling the washes, followed by washing once with high salt buffer (buffer A with 1.05 M NaCl). To isolate proteinbound DNA, filters were incubated for 5 minutes in heated (65°C) SDS buffer (10 mM Tris, pH 7.7, 1 mM EDTA, 1% w/v SDS), followed by centrifugation. The SDS incubation was repeated once more, and the SDS fractions were pooled. All fractions [low salt (L), high salt (H), SDS (S)] were precipitated with 0.7 volumes of isopropanol. After incubation at 220°C, DNA was pelleted by centrifugation and resuspended in DNA loading buffer (0.005% w/v bromophenol blue, 5% v/v glycerol) prior to resolution on a 1% w/v agarose gel. Gels were stained postelectrophoresis with 1 mg ml 21 ethidium bromide. ATP Hydrolysis Assay Using [g 32 P]ATP. Topo II-mediated ATP hydrolysis was monitored by thin layer chromatography, as previously described (Kingma et al., 2001 ), but with the following modifications. Human topo IIa (31 nM) was incubated in reaction buffer A in the presence of 1.2 mg (6 pmol) pBluescript-KS 1 plasmid DNA and the indicated drug for 10 minutes at room temperature prior to initiating the reaction with the addition of 3 mCi [g-32 P]ATP (3000 Ci/mmol; PerkinElmer). Reactions were incubated at 37°C. At the indicated time intervals, 2 ml aliquots were spotted onto prewashed (distilled water) polyethyleneimine-impregnated cellulose plates (Sigma-Aldrich) and air dried. Reaction products were resolved by developing plates with freshly prepared 400 mM NH 4 HCO 3 . Plates were air dried and exposed to autoradiographic film. Spots corresponding to free phosphate were excised from the thin layer chromatography plates and quantified using a scintillation counter. For assays utilizing apyrase, reactions contained 2 mU apyrase in place of topo IIa in identical buffer conditions, but in the absence of DNA.
Malachite Green ATPase Assay. To determine the kinetics of topo IIa-mediated ATP hydrolysis, a colorimetric assay utilizing malachite green and ammonium molybdate was used (Tretter and Berger, 2012) . In a 96-well plate, 50 ml reactions containing topo IIa (8 U) were prepared in reaction buffer A containing varying concentrations of salicylate or novobiocin as well as 2 mg (10.2 pmol) pBluescript-KS 1 DNA. Reactions were initiated by the addition of increasing concentrations of ATP (disodium salt; Topogen), covered, and incubated at 37°C for 25 minutes. Immediately following the incubation, 200 ml malachite green reagent (0.034% w/v malachite green, 3.4% v/v ethanol, 10 mM ammonium molybdate, 1 N HCl) was added, and absorbance was measured at 650 nm. Reactions examining liberation of phosphate by apyrase were carried out under identical buffer conditions using 2 mU apyrase but in the absence of DNA.
ATP-Independent, Prestrand Passage Cleavage Assay. Topo IIa-or b-mediated cleavage of plasmid DNA in the absence of nucleotide triphosphate and magnesium was carried out as previously described (Bandele and Osheroff, 2009 ) with the following modifications. Topo IIa or topo IIb (41.4 nM homodimer) was incubated in a reaction with 200 ng (0.64 pmol) pBR322 with increasing concentrations of salicylate or ICRF-193. The final buffer contained 10 mM Tris, pH 7.7, 50 mM NaCl, 50 mM KCl, 0.1 mM EDTA, 5 mM CaCl 2 , and 0.03 mg ml 21 bovine serum albumin. Reactions were incubated at 37°C for 15 minutes prior to the addition of SDS (1% w/v), and incubation was continued for an additional 5 minutes. Reactions were then digested by the addition of 8 mg proteinase K and incubated at 56°C for 30 minutes. DNA products were resolved on a 1.4% w/v agarose gel containing 0.7 mg ml 21 ethidium bromide. Poststrand Passage Cleavage Assay. Topo IIa-mediated poststrand passage cleavage was measured, as described above, for prestrand passage cleavage, except that reactions contained 0.5 mM AMP-PNP.
ATP-Independent DNA Religation Assay. Topo IIa-mediated religation of plasmid DNA in the absence of a nucleotide triphosphate was carried out as previously described (Osheroff, 1989) . Topo IIa (41.4 nM homodimer) was incubated in a reaction with 200 ng (0.64 pmol) pBR322 plasmid DNA in a reaction buffer containing 10 mM Tris, pH 7.7, 50 mM NaCl, 50 mM KCl, 0.1 mM EDTA, 5 mM CaCl 2 , and 0.03 mg ml 21 bovine serum albumin at 37°C for 10 minutes. Immediately after, samples received either salicylate (to a final concentration of 30 mM) or vehicle, followed by the addition of 2 ml 100 mM EDTA to all samples. Reactions were then reinitiated by the addition of 2 ml 100 mM MgCl 2 and transferred immediately to ice. After the indicated time points (15, 30, or 60 seconds), reactions were stopped by the addition of SDS (1% w/v) and incubated for an additional 5 minutes at 37°C. Reactions were then incubated with 8 mg proteinase K at 56°C for 30 minutes. DNA products were resolved on a 1.4% w/v agarose gel containing 0.7 mg ml 21 ethidium bromide. Kinetoplast DNA Assay. The effect of salicylate on topo IIa and topo IIb catalytic activity was examined, as previously described (Bau and Kurz, 2011) , with the following modifications. Human topo IIa or topo IIb (32 nM) was incubated with 200 ng kinetoplast DNA (Topogen) in reaction buffer A for 10 minutes on ice prior to the addition of ATP (0.5 mM) and further incubation at 37°C for 8 minutes. Reactions were stopped by the addition of SDS (1% w/v), and reaction products were resolved on a 1% w/v agarose gel containing 0.7 mg ml 21 ethidium bromide.
Results
Salicylate Does Not Intercalate DNA and Does Not Interfere with Topo II-DNA Binding. The inhibition of topo II catalytic activity can occur at one of several stages of the catalytic cycle. As a consequence, multiple independent approaches are required to determine the mechanism of drug-mediated inhibition of topo II. Some topo II catalytic inhibitors intercalate DNA, binding either the major or minor groove (Larsen et al., 2003; Ketron et al., 2012) ; distortion of the DNA backbone can preclude topo II-DNA interaction. The ability of salicylate to intercalate DNA was assessed using a topo I-unwinding assay (Pommier et al., 1987) . Supercoiled pHOT1 plasmid DNA was relaxed by the addition of topo I. The addition of a known DNA intercalator (mAMSA) (Larsen et al., 2003; Nitiss, 2009b) results in negative supercoiling of the plasmid, which migrates with greater mobility than its relaxed counterpart (Fig. 1A) . In contrast, the addition of increasing concentrations of salicylate did not alter the mobility of the relaxed topoisomers, indicating that salicylate does not intercalate DNA (Fig. 1A) .
The ability of salicylate to interact with DNA was also assessed using a fluorescence-based ethidium bromide displacement assay (Fortune and Osheroff, 1998) . The fluorescence of ethidium bromide is greatly enhanced upon intercalation into DNA, which is quantifiable by fluorescence spectroscopy. As expected, the addition of mAMSA was accompanied by a concomitant decrease in ethidium bromide fluorescence (Fig.  1B) , indicative of ethidium bromide displacement. In contrast, the addition of increasing concentrations of salicylate did not alter the intensity of ethidium bromide fluorescence (Fig. 1C) . Together, these findings suggest that salicylate does not inhibit topo IIa catalytic activity by intercalating DNA.
As an alternative approach to examine whether salicylate interferes with the ability of topo II to bind DNA, we used EMSAs. Robust topo II-DNA binding was observed when a radiolabeled probe containing a strong topo II binding site was used (Fig. 1D) (Kurz et al., 2000; Peebles et al., 2001) . The presence of topo II in this complex was confirmed by both competition assays with unlabeled self and nonspecific doublestranded oligonucleotides and by supershift assay using a topo IIa-specific antiserum (Supplemental Fig. 1) . Addition of hypericin, a previously established catalytic inhibitor of topo II that blocks DNA binding (Peebles et al., 2001) , decreased the topo II-DNA interaction in a dose-dependent manner (Fig. 1D) . In contrast, addition of increasing concentrations of salicylate had no effect on either the formation or mobility of the topo II-DNA complex (Fig. 1D) , indicating that salicylate does not alter the ability of topo II to bind DNA. To corroborate our findings, we used purified human topo IIa and performed EMSAs using hypericin and salicylate. As demonstrated in Fig. 1E , topo II efficiently binds the entire pool of radiolabeled probe; however, this interaction is prevented in the presence of hypericin, but unaffected by the addition of salicylate, confirming our findings using cell extracts (Fig. 1D) .
Topo IIa ATPase Activity Is Decreased in the Presence of Salicylate. Many compounds have been reported to inhibit the ATPase activity of topo II (Hu et al., 2006; Qin et al., 2007) ; some are competitive inhibitors of ATP binding, whereas others indirectly decrease ATPase activity by inhibiting topo II from reentering the catalytic cycle, thus reducing ATP hydrolysis. Using purified human topo IIa, we monitored enzyme-mediated ATP hydrolysis in vitro by thin layer chromatography. Novobiocin, a competitive inhibitor of ATP that binds within the ATP-binding pocket, significantly diminished topo IIa-mediated ATP hydrolysis ( Fig. 2A) . Consistent with previous reports (Morris et al., 2000; Chène et al., 2009) , the closed clamp inhibitor ICRF-193 also reduced topo IIa-mediated ATP hydrolysis ( Fig. 2A) . Addition of salicylate led to a dose-dependent reduction in topo IIa-mediated ATP hydrolysis (Fig. 2B) .
To elucidate the nature of salicylate-mediated inhibition of ATPase activity, we quantified the rates of free phosphate generation during topo IIa-mediated ATP hydrolysis. Inhibition by competitive inhibitors of ATP, such as AMP-PNP and novobiocin, can be overcome by increases in substrate (ATP) concentration. This is in contrast to noncompetitive inhibitors of topo II-mediated ATP hydrolysis, such as sodium orthovanadate The topo I-mediated DNA-unwinding assay was completed, as described in Materials and Methods. pHOT1 plasmid was incubated with topo I prior to the addition of either mAMSA (10, 50, or 100 mM) or salicylate (1, 3, or 10 mM). Reaction products were resolved on an agarose gel containing 0.2 mg ml 21 chloroquine prior to visualization with ethidium bromide. (B and C) Supercoiled plasmid DNA (5 nM) was incubated in the presence of ethidium bromide (EtBr) and increasing concentrations of mAMSA (B) or salicylate (sal) (C). Fluorescence values (excitation 510 nm/emission 595 nm) are plotted as mean fold increase over buffer, with error bars representing the standard deviation from three independent experiments. (D) Topo II-DNA binding is not altered by salicylate but is decreased by a known catalytic inhibitor of topo II-DNA binding, hypericin. MCF-7 nuclear extracts were incubated with a 32 P-labeled double-stranded oligonucleotide containing a strong topo II binding site (Kurz et al., 2000; Peebles et al., 2001) in the presence of increasing concentrations of hypericin or salicylate. Reaction products were resolved by nondenaturing polyacrylamide gel electrophoresis, dried, and exposed to autoradiographic film. (E) Reactions described in D were repeated using purified human topo II in the presence of hypericin or salicylate. Binding reactions contained equal moles of binding site and topo II (1.6 fmol) and were incubated at room temperature for 30 minutes. Reaction products were processed as in D. RLX, relaxed DNA; SC, supercoiled DNA.
Salicylate Inhibits Topoisomerase IΙa DNA Cleavage and ICRF-193 (Harkins et al., 1998; Baird et al., 1999; Morris et al., 2000) . To examine whether salicylate acts in a competitive or noncompetitive manner, we used the quantitative, colorimetric malachite green assay. In the presence of novobiocin, a competitive inhibitor of ATP binding, increasing concentrations of ATP reversed inhibition by novobiocin (Fig.  2C) . In contrast, even in the presence of increasing ATP concentrations, salicylate-mediated ATPase inhibition was not altered, indicating that salicylate is a noncompetitive inhibitor of topo IIa-ATPase activity (Fig. 2D) . As salicylate has been reported to inhibit other cellular enzymes (Yin et al., 1998; Deng et al., 2001) and to examine whether salicylatebased inhibition of ATPase activity is more broadly observed, we investigated whether salicylate inhibits the ATPase activity of apyrase, an E-type ATPase (Handa and Guidotti, 1996) . In contrast to salicylate-mediated inhibition of topo IIa ATPase activity, salicylate did not alter apyrase catalytic activity even at high concentrations of drug (Fig. 2, E and F Classen et al., 2003) . Similarly, nonhydrolyzable ATP analogs, such as AMP-PNP, trap topo II on DNA by binding to the ATP-binding domains to induce N-terminal clamp closure. In both cases, the enzyme is unable to dissociate from DNA after strand passage, preventing it from re-entering the catalytic cycle, and trapping the enzyme in a noncovalent protein clamp on DNA.
Utilizing a filter-binding assay, we measured DNA trapped in topo IIa closed clamps. In this assay, glass fiber filters that bind protein, but not free DNA, were used. In the absence of topo IIa, supercoiled plasmid DNA readily passes through the filter and is collected in the flow-through/low salt wash ( Fig. 3 ; DNA alone, lane L). In the presence of topo IIa and ATP, the plasmid DNA is relaxed but freely passes through the filter and is also collected in the low-salt wash. The relaxed DNA is observed as a slower migrating species on the DNA gel ( Fig. 3 ; ATP, lane L). In contrast, in the presence of AMP-PNP, topo IIa-mediated DNA relaxation is inhibited, as indicated by the supercoiled DNA observed in lane L of the AMP-PNP sample, and a portion of the DNA becomes trapped on the filter in a topo IIa closed clamp. This DNA is only liberated following the denaturation of topo II with hot SDS-containing buffer The detection of free phosphate release by apyrase was quantified using thin layer chromatography as in A using 2 mU apyrase. (F) Hydrolysis of free phosphate during ATP hydrolysis by apyrase was examined using malachite green. Reactions were incubated at 25°C for 8 minutes prior to the addition of the malachite green reagent. Absorbance readings were measured at 650 nm.
( Fig. 3 ; AMP-PNP, lane S). Although addition of salicylate led to an inhibition of DNA relaxation ( Fig. 3 ; ATP 1 10 mM sal, lane L, as compared with ATP, lane L), consistent with salicylate's catalytic inhibition of topo IIa (Bau and Kurz, 2011) , salicylate did not stabilize the enzyme in a closed clamp on DNA ( Fig. 3 ; ATP 1 10 mM sal, lane S).
Salicylate Inhibits the Cleavage Reaction of Topo IIa. As our experimental findings indicate that salicylate does not inhibit topo IIa-DNA interaction or trigger the stabilization of a closed clamp on DNA, we hypothesized that salicylate may inhibit topo II at the DNA cleavage step. Previously, we observed that ATP-dependent topo IIa cleavage activity is completely inhibited by 10 mM salicylate. In the presence of ATP, both prestrand and poststrand passage DNA cleavage are supported, with the reaction heavily favoring poststrand passage DNA cleavage (Burden et al., 2001 ). In the absence of ATP, topo II binds DNA and establishes a cleavage-religation equilibrium prior to strand passage. Although topo II requires Mg 21 for coordination of the cleavage-religation event, in the presence of Ca 21 the cleavage-religation equilibrium shifts to favor stabilization of the cleaved complex (Bandele and Osheroff, 2009) , allowing for this step to be experimentally isolated. In the presence of Ca 21 , topo II cleaves but is unable to religate DNA, trapping the enzyme-DNA complex. The removal of topo II by the addition of a denaturant (SDS) to the reaction and digestion of the protein complex allows for visualization of a linear DNA band, corresponding to the prestrand passage DNA cleavage event. As ATP is required for strand passage, the absence of ATP in the reaction allows for isolation of the prestrand passage event. To examine the effects of salicylate on topo IIa prestrand passage DNA cleavage, we carried out a plasmid DNA cleavage assay in the presence of Ca 21 and absence of ATP. Incubation with increasing concentrations of salicylate led to a dose-dependent loss of cleaved DNA, represented by the loss of the linear DNA band (Fig. 4, A and B) . Furthermore, we observed that salicylate prevents topo IIa-mediated singlestrand DNA cleavage, as shown by the decreased intensity of the slower mobility nicked circular band (Bandele and Osheroff, 2009 ). ICRF-193, which inhibits enzyme activity postcleavage and strand passage, had no effect on the formation of cleaved DNA or on levels of nicked circular DNA (Fig. 4, A and C) .
Together, these results indicate that salicylate can block the topo II-mediated prestrand passage DNA cleavage event.
To determine whether salicylate has similar effects on poststrand passage DNA cleavage, we repeated the above experiment, but with the inclusion of AMP-PNP in the reaction buffer (Robinson and Osheroff, 1991) . The addition of this nonhydrolyzable ATP analog permits strand passage to occur. Carrying out the reaction in the presence of Ca 21 thus isolates poststrand passage DNA cleavage. In the presence of AMP-PNP and Ca 21 , incubation with increasing concentrations of salicylate led to a dose-dependent loss of cleaved DNA, represented by the loss of the linear DNA band (Fig. 4, D and  E) . Together, these results indicate that salicylate can block both topo II-mediated prestrand and poststrand DNA cleavage reactions.
We subsequently examined the effect of salicylate on topo IImediated DNA religation. Similar to the experiment above, we trapped kinetically competent, topo II-DNA complexes in the presence of Ca 21 . After sequestration of the excess Ca 21 ions by the addition of EDTA, reintroduction of Mg 21 allows for religation of the linear band (Osheroff, 1989) . To examine whether salicylate impacts the religation of DNA by topo II, we initiated reactions with Mg 21 in the presence or absence of salicylate (Fig. 4F ). Our experiments demonstrate that the religation of DNA occurs almost instantaneously and is not impeded in the presence of 30 mM salicylate, a concentration that severely impairs DNA cleavage.
Salicylate Preferentially Inhibits the a Isoform of Human Topo II. Whereas most catalytic inhibitors and poisons of human topo II act on both the a and b isoforms, a limited number of compounds have been described that preferentially inhibit one isoform (Gao et al., 1999; Toyoda et al., 2008; Auzanneau et al., 2012) . To examine whether salicylate can inhibit the b isoform of topo II with equal potency, we performed decatenation assays utilizing purified topo IIa and topo IIb. Strikingly, we found that salicylate preferentially inhibits the activity of the topo IIa isoform, demonstrating complete inhibition of decatenation at 1 mM, whereas no inhibition of the topo IIb isoform was observed at concentrations up to 10 mM (Fig. 5A) . To determine whether preferential inhibition was observed when assessing prestrand passage, we repeated the plasmid cleavage assay in the presence of Ca 21 and the absence of ATP with purified human topo IIb (Fig. 5, B and C) . Similar to the decatenation assay, no inhibition of topo IIb was observed at concentrations up to 30 mM, although inhibition of topo IIb was observed at 50 mM salicylate, a suprapharmacologic dose.
Discussion
Compounds that disrupt the catalytic activity of topo II are broadly classed with multiple mechanisms of action (Fig. 6) . Topo II poisons (such as doxorubicin and etoposide) stabilize the topo II-DNA cleavable complex, leading to an accumulation of DNA double-stranded breaks, thus overwhelming the cell's capacity for repair. In contrast, catalytic inhibitors inhibit topo II without directly inducing DNA strand breaks. Previously, we identified salicylate as a novel catalytic inhibitor of human topo II (Bau and Kurz, 2011) . Importantly, we determined that pretreatment of cells with salicylate attenuates topo II poison-induced DNA double-stranded break formation, thereby decreasing the cytotoxic effects of To analyze topo IIa closed clamps, filter-binding assays were used, as outlined in Materials and Methods. Topo IIa (33 nM) was incubated with 15.5 nM (600 ng) pBluescript DNA in a reaction containing 0.5 mM ATP, 0.5 mM AMP-PNP, or 0.5 mM ATP with 10 mM salicylate (sal). Reaction products were incubated on glass fiber filters, centrifuged, and washed twice with low-salt buffer (fraction L). Filters were then washed in a high-salt (1.05 M NaCl) buffer (fraction H). Lastly, filters were incubated in a buffer containing 1% SDS (heated to 65°C) for 10 minutes prior to centrifugation (fraction S). DNA in each fraction was precipitated, and recovered DNA products were resolved by agarose gel electrophoresis. doxorubicin and etoposide. This effect is specific for topo II and independent of salicylate-mediated inhibition of cyclooxygenases or nuclear factor kB (Bau and Kurz, 2011) . Given that salicylate-based therapeutics, including aspirin (acetylsalicylic acid), are widely accessible and widely consumed, we sought to determine the biochemical mechanism underlying the salicylate-mediated inhibition of topo II.
We tested the possibility that salicylate could disrupt the topo II-DNA interaction through distortion of the DNA helical structure (Fig. 1) . DNA intercalation is typically observed with compounds such as mAMSA and doxorubicin that contain planar aromatic rings and positive charges, enhancing their interaction with DNA (Armitage, 2005) . Whereas salicylate, also known as 2-hydroxybenzoate, contains an aromatic ring, its structure is compact and anionic, thus limiting its potential for direct interaction with DNA. To further corroborate our findings, we used gel shift assays that demonstrated no effect of salicylate on topo II-DNA binding (Fig. 1) .
We observed that salicylate decreases topo IIa-mediated ATP hydrolysis (Fig. 2B ). This inhibition was noncompetitive, as it was not overcome by increasing the concentration of ATP (Fig. 2D) ; such an effect on topo II has been observed with vanadate and bisdioxopiperazines (Harkins et al., 1998) . This is in contrast to competitive inhibitors, such as AMP-PNP, novobiocin (Fig. 2C) , and quinoline aminopurine compound 1, in which the effectiveness of inhibition is decreased with a corresponding increase in ATP (Hu et al., 2006; Chène et al., 2009) . Both competitive and noncompetitive inhibitors of topo II ATPase activity can promote the formation of enzyme closed clamps (Harkins et al., 1998; Morris et al., 2000; Classen et al., 2003; Vaughn et al., 2005) . Compounds that promote topo II closed clamps permit DNA cleavage, strand passage, and religation, but prevent dissociation of topo II from the DNA, thereby trapping the enzyme. However, despite decreasing topo IIa-mediated ATP hydrolysis, the addition of salicylate failed to stabilize topo II in a closed clamp on DNA (Fig. 3 ), even at high (100 mM) concentrations (J. T. Bau and E. U. Kurz, unpublished observations). We did, however, observe complete inhibition of topo IIa catalytic activity ( Fig. 3 ; ATP 1 10 mM sal, lane L), consistent with our earlier work (Bau and Kurz, 2011) . Thus, in the case of salicylate and topo II, the apparent noncompetitive inhibition of ATPase activity appears to be an indirect effect of inhibition elsewhere in the catalytic cycle.
Cleavage assays performed in the presence of Ca 21 and the absence of a nucleotide triphosphate allow for the interrogation of DNA cleavage in the absence of strand passage (Osheroff and Zechiedrich, 1987; Bandele and Osheroff, 2009; Schmidt et al., 2012) . Using this approach, we demonstrate that salicylate inhibits the prestrand passage DNA cleavage activity of topo IIa. This mechanism of inhibition has previously been observed with two other catalytic inhibitors of topo II: merbarone and staurosporine (Lassota et al., 1996; Fortune and Osheroff, 1998) . Although these three agents inhibit the ATP-independent nucleophilic attack of the DNA by the catalytic site tyrosine, inhibition of topo II catalytic activity by salicylate (Fig. 2) and staurosporine (Lassota et al., 1996) is also associated with noncompetitive inhibition of topo II ATPase activity. In contrast, merbarone has been reported not to impact topo II ATPase activity (Fortune and Osheroff, 1998) , although this is not the case in our hands (J. T. Bau and E. U. Kurz, unpublished observation) . In fact, inhibition of topo II-mediated ATP hydrolysis secondary to inhibition elsewhere in the catalytic cycle has been commonly observed among catalytic inhibitors of topo II (Robinson et al., 1993; Lassota et al., 1996) . In addition to inhibition of prestrand passage DNA cleavage, we also observed salicylate-mediated inhibition of poststrand passage DNA cleavage (Fig. 4, D and E) . Despite the ability of salicylate to impair DNA cleavage both pre-and poststrand passage, the compound does not affect DNA religation, as resealing of the cleaved DNA was almost instantaneous (Fig. 4F) . Together, these observations indicate that salicylate selectively acts upon DNA cleavage and not at other steps within the enzymatic cycle.
Somewhat surprisingly, we found that salicylate inhibits topo II with at least 10-fold greater selectivity for the a isoform (Fig. 5) . Previous work has identified topo IIa-or topo IIb-specific poisons, with selectivity ranging from 1.5-fold to greater than 10-fold (Gao et al., 1999; Bandele and Osheroff, 2007; Toyoda et al., 2008) . Recent work has reported the first isoform-selective catalytic inhibitors of topo IIa, polyphenolic ellagitannin derivatives (Auzanneau et al., 2012) . The biochemical basis of isoform selectivity with these compounds and salicylate remains unknown. Human topo IIa and topo IIb share very similar catalytic activity and are highly conserved, with 78% amino acid identity in the N-terminal three-quarters of the enzyme, but falling to only 34% identity in the C terminus (Austin and Marsh, 1998) . Whether this C-terminal region plays a role in determining the selectivity of salicylate for the a isoform may be revealed by further research mapping the region of interaction. Taken together, these studies highlight important findings that may aid in our understanding of the chemical requirements necessary for isoform selective catalytic inhibition of topo II. There is increasing interest in the identification and development of isoform-selective topo II poisons and inhibitors. This has emerged largely because treatment with topo II poisons is associated with a number of side effects, including cardiomyopathy and secondary malignancies (particularly mixed lineage leukemia translocation-driven leukemias) (Azarova et al., 2007; Cowell et al., 2012; Zhang et al., 2012) . Recent work has established that poisoning of topo IIb by these chemotherapeutics drives both cardiotoxicity (Zhang et al., 2012) and development of secondary malignances (Cowell et al., 2012) . Interestingly, coadministration with topo II catalytic inhibitors (specifically bisdioxopiperazines) significantly reduces the risk of these side effects in patients (Cvetkovi c and Scott, 2005; Vrooman et al., 2011) . However, stabilization of topo II in closed clamps on DNA results in topological blocks that can lead to deleterious cytologic defects (chromosomal aberrations, endoreduplication) (Germe and Hyrien, 2005) . This shortcoming may be overcome with the development of isoform-specific topo II catalytic inhibitors that do not leave the enzyme trapped on DNA.
Salicylate is a widely used drug that has multiple mechanisms of action. In addition to our work identifying it as a catalytic inhibitor of topo IIa, salicylate is known to inhibit inhibitory nuclear factor kB kinase and the heat shock family member glucose-regulated protein 78 (Yin et al., 1998; Deng et al., 2001) , whereas, in contrast, it is an activator of AMPactivated protein kinase (Hawley et al., 2012) . Aspirin and related salicylates remain among the most widely used drugs in the world, with an estimated 40,000 metric tons of aspirin consumed annually (Warner and Mitchell, 2002) . Although salicylate is not sufficiently potent to be cytotoxic at clinically achievable concentrations, our previous work demonstrated that pretreatment of cells with salicylate attenuates both doxorubicin and etoposide cytotoxicity (Bau and Kurz, 2011) . Whether coadministration of salicylate reduces the efficacy of antitumor therapy in xenograft model systems remains an ongoing area of investigation. This work may provide justification for discouraging the use of aspirin and related drugs in patients undergoing cancer treatment using topo II poisons.
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